The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid-Responsive Diseases
OBJECTIVES: I. Determine the long-term safety and efficacy of acitretin in patients with
psoriasis, cutaneous disorders of keratinization, multiple basal cell carcinomas, or other
retinoid-responsive diseases or malignancies.
OUTLINE: Patients receive oral acitretin daily in the absence of disease progression or
PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study.
Primary Purpose: Treatment
John J. DiGiovanna, MD
National Cancer Institute (NCI)
United States: Federal Government
|Intramural Research Program||Bethesda, Maryland 20892|